These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 16333125

  • 1. Association between cellular human immunodeficiency virus DNA level and immunological parameters in patients with undetectable plasma viremia level during highly active antiretroviral therapy.
    Sarmati L, Parisi SG, Nicastri E, d'Ettorre G, Palmisano L, Andreotti M, Andreoni C, Giuliano M, Gatti F, Boldrin C, Palù G, Vullo V, Vella S, Andreoni M.
    J Clin Microbiol; 2005 Dec; 43(12):6183-5. PubMed ID: 16333125
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Detection and quantification of proviral HIV-1 184 M/V in circulating CD4(+) T cells of patients on HAART with a viremia less than 1,000 copies/ml.
    Mohey R, Jørgensen LB, Møller BK, Black FT, Kjems J, Obel N.
    J Clin Virol; 2005 Dec; 34(4):257-67. PubMed ID: 16286049
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Significant link between sCD30 changes and HIV viremia in patients treated with HAART.
    Biswas P, Cozzi-Lepri A, Delfanti F, Galli A, Colangeli V, Moioli MC, Scarchilli A, Abrescia N, Vigevani G, D'Arminio-Monforte A, Novati R, Lazzarin A.
    J Med Virol; 2006 Dec; 78(12):1513-9. PubMed ID: 17063513
    [Abstract] [Full Text] [Related]

  • 6. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, Goh LE, Lindback S, Sereni D, Gazzard B, Montaner J, Stellbrink HJ, Lazzarin A, Ponscarme D, Staszewski S, Mathiesen L, Smith D, Finlayson R, Weber R, Wegmann L, Janossy G, Kinloch-de Loes S, QUEST Study Group.
    Clin Infect Dis; 2007 Aug 01; 45(3):381-90. PubMed ID: 17599319
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cellular HIV-1 DNA quantitation in patients during simplification therapy with protease inhibitor-sparing regimens.
    Sarmati L, Parisi SG, Nicastri E, d'Ettorre G, Andreoni C, Dori L, Gatti F, Montano M, Buonomini AR, Boldrin C, Palù G, Vullo V, Andreoni M.
    J Med Virol; 2007 Jul 01; 79(7):880-6. PubMed ID: 17516532
    [Abstract] [Full Text] [Related]

  • 11. Relationships between HIV disease history and blood HIV-1 DNA load in perinatally infected adolescents and young adults: the ANRS-EP38-IMMIP study.
    Avettand-Fenoel V, Blanche S, Le Chenadec J, Scott-Algara D, Dollfus C, Viard JP, Bouallag N, Benmebarek Y, Rivière Y, Warszawski J, Rouzioux C, Buseyne F.
    J Infect Dis; 2012 May 15; 205(10):1520-8. PubMed ID: 22427678
    [Abstract] [Full Text] [Related]

  • 12. Development of methods for coordinate measurement of total cell-associated and integrated human immunodeficiency virus type 1 (HIV-1) DNA forms in routine clinical samples: levels are not associated with clinical parameters, but low levels of integrated HIV-1 DNA may be prognostic for continued successful therapy.
    Carr JM, Cheney KM, Coolen C, Davis A, Shaw D, Ferguson W, Chang G, Higgins G, Burrell C, Li P.
    J Clin Microbiol; 2007 Apr 15; 45(4):1288-97. PubMed ID: 17314225
    [Abstract] [Full Text] [Related]

  • 13. Early plasmacytoid dendritic cell changes predict plasma HIV load rebound during primary infection.
    Pacanowski J, Develioglu L, Kamga I, Sinet M, Desvarieux M, Girard PM, Hosmalin A.
    J Infect Dis; 2004 Nov 15; 190(10):1889-92. PubMed ID: 15499547
    [Abstract] [Full Text] [Related]

  • 14. Decay of human immunodeficiency virus type 1 unintegrated DNA containing two long terminal repeats in infected individuals after 3 to 8 years of sustained control of viremia.
    McDermott JL, Martini I, Ferrari D, Bertolotti F, Giacomazzi C, Murdaca G, Puppo F, Indiveri F, Varnier OE.
    J Clin Microbiol; 2005 Oct 15; 43(10):5272-4. PubMed ID: 16207994
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. No evidence of an association between transient HIV viremia ("Blips") and lower adherence to the antiretroviral medication regimen.
    Miller LG, Golin CE, Liu H, Hays RD, Hua J, Wenger NS, Kaplan AH.
    J Infect Dis; 2004 Apr 15; 189(8):1487-96. PubMed ID: 15073687
    [Abstract] [Full Text] [Related]

  • 17. Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy.
    Di Mascio M, Ribeiro RM, Markowitz M, Ho DD, Perelson AS.
    Math Biosci; 2004 Apr 15; 188():47-62. PubMed ID: 14766093
    [Abstract] [Full Text] [Related]

  • 18. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy.
    Cohen Stuart JW, Velema M, Schuurman R, Boucher CA, Hoepelman AI.
    J Med Virol; 2009 Mar 15; 81(3):441-5. PubMed ID: 19152397
    [Abstract] [Full Text] [Related]

  • 19. Clinical impact of GB virus C viremia on patients with HIV type 1 infection in the era of highly active antiretroviral therapy.
    Sheng WH, Hung CC, Wu RJ, Wang JT, Chen PJ, Chang SC, Kao JH.
    Clin Infect Dis; 2007 Feb 15; 44(4):584-90. PubMed ID: 17243064
    [Abstract] [Full Text] [Related]

  • 20. Predictors of plasma human immunodeficiency virus type 1 RNA control after discontinuation of highly active antiretroviral therapy initiated at acute infection combined with structured treatment interruptions and immune-based therapies.
    Lafeuillade A, Poggi C, Hittinger G, Counillon E, Emilie D.
    J Infect Dis; 2003 Nov 15; 188(10):1426-32. PubMed ID: 14624367
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.